CoA Therapeutics, Inc.
CoA Therapeutics is dedicated to developing therapies targeting Coenzyme A (CoA) for patients with genetic disorders such as PKAN, organic acidurias, and other diseases related to CoA sequestration. Founded in 2018, the company leverages scientific advances in the CoA pathway to create novel treatments for rare and difficult-to-treat genetic disorders.
Industries
Nr. of Employees
small (1-50)
CoA Therapeutics, Inc.
Palo Alto, California, United States, North America
Products
Preclinical and clinical-stage small-molecule programs targeting CoA biosynthesis
Therapeutic development programs focused on small molecules that bind pantothenate kinase isoforms to prevent feedback inhibition and increase CoA levels, intended to treat PKAN and organic acidurias.
Preclinical and clinical-stage small-molecule programs targeting CoA biosynthesis
Therapeutic development programs focused on small molecules that bind pantothenate kinase isoforms to prevent feedback inhibition and increase CoA levels, intended to treat PKAN and organic acidurias.
Services
Drug discovery and development for CoA-related disorders
End-to-end internal development of small-molecule therapeutic candidates that modulate CoA biosynthesis for treatment of PKAN and organic acidurias.
Drug discovery and development for CoA-related disorders
End-to-end internal development of small-molecule therapeutic candidates that modulate CoA biosynthesis for treatment of PKAN and organic acidurias.
Expertise Areas
- CoA pathway biology and modulation
- Rare genetic disease drug development
- Pantothenate kinase-associated neurodegeneration (PKAN)
- Organic acidurias (propionic and methylmalonic acidemias)
Key Technologies
- Small-molecule therapeutics
- Enzyme-targeted drug design (pantothenate kinase modulation)
- Metabolic pathway analysis
- Biochemical assays for CoA and thioesters